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INTRODUCTION 
 
Cancer cells escape normal growth control mechanisms as a 
consequence of activating (i.e., gain-of-function) mutations and/or 
increased expression of one or more cellular proto-oncogenes and/or 
inactivating (i.e., loss-of function) mutations and/or decreased 
expression of one or more tumor suppressor genes. Most oncogene 
and tumor suppressor gene products are components of signal 
transduction pathways that control cell cycle entry or exit, promote 
differentiation, sense DNA damage and initiate repair mechanisms, 
and/or regulate cell death programs. Several oncogenes and tumor 
suppressor genes belong to the same signaling pathway. Nearly all 
tumors have mutations in multiple oncogenes and tumor suppressor 
genes, indicating that cells employ multiple parallel mechanisms to 
regulate cell growth, differentiation, DNA damage control, and death.  
The PTEN gene was discovered only in 1997 as a new tumor 
suppressor, and yet it is now known to play major roles not only in 
suppressing cancer but also in embryonic development, cell migration 
and apoptosis (reviews include Maehama and Dixon, 1999; Cantley 
and Neel, 1999; Besson et al., 1999; Tamura et al., 1999c; Ali et al., 
1999; Di Cristofano and Pandolfi, 2000; Vazquez and Sellers, 2000; 
Bonneau and Longy, 2000; Simpson and Parsons, 2001). Altough an 
increasing numbers of biologically important phosphatases are being 
characterized (Li and Dixon, 2000; Tonks and Neel, 1996), but PTEN 
has been the focus of particularly intense interest because of its central 
role in suppressing malignancy.  
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CLONING OF PTEN  
The PTEN (phosphatase and tensin homolog deleted on 
chromosometen)/MMAC (mutated in multiple advanced cancers) was 
identified virtually simultaneously by two groups (Ling al., 1992; 
Webster et al., 1998) as a candidate tumor suppressor gene located at 
10q23; another group (Moscatello et al.1998) identified the same gene 
in a search for new dual-specificity phosphatases  and named it TEP-1 
(TGF-β-regulated and epithelial cell-enriched phosphatase). The 
PTEN protein sequence suggested that is was a member of the 
protein-tyrosine phosphatase (PTP) gene superfamily . PTEN catalytic 
domains contain the canonical sequence HCXXGXXRSyT, known as 
the PTP ‘‘signature motif’’ (Rasheed et al. 1997) (see figure 1A); the 
presence of this motif within any protein makes it a virtual certainty 
that it has PTP activity. In particular, the PTEN sequence suggested 
that it was a dual-specificity phosphatase, an enzyme that, as its name 
implies, typically dephosphorylate phosphotyrosine, phosphoserine, 
and/or phosphothreonine in vitro. However, PTEN is an unusual 
phosphatase in the sense that it dephosphorylate both lipids and 
proteins. PTEN protein contains 403 amino acids and can be divided 
into three domains: a phosphatase domain (1–185), a C2 domain 
(186–352), and a tail domain (353–403) (Lee et al. 1999) (see figure 
2).  
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Figure1. A. Conserved amino acid sequence motif present in inositol 
phosphatases. The amino acid sequence of human PTEN, Salmonella 
dublin SopB, Salmonella flexneri IpgD, human inositol 
polyphosphatase type I and type II are indicated. B.Alignment of 
PTEN signature motifs. The amino acid sequences of human (Homo 
sapiens), mouse (Mus musculus), rat (Rattus norvegicus), dog (Canis 
familiaris), worm (Caenorhabditis elegans), fly  (Drosophila 
melanogaster) and yeast (Saccharomyces cerevisiae) PTEN are 
shown. The crucial catalytic cysteine and the invariant basic residues 
are highlighted in red and blue, respectively. 
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Figure 2. The N-terminal-phosphatase domain (amino acids 1 185) is 
shown with the catalytic core. The C-terminal domain (amino acids 
186 403) C2 domain -lipid-bindin PEST domains-regulate protein 
stability PDZ domain-is important in protein-protein interactions. CK2 
phosphorylation sites -are important for stability 
 9 
 
The phosphatase and C2 domains are required for efficient membrane 
binding (Das et al. 2003). Mutations of the phosphatase motifof PTEN 
do not perturb membrane binding but inhibit PIP3 catalysis. 
Interestingly, amino acids 1–14 encode a PIP2 binding domain and 
recent evidence demonstrates that PIP2 binding at this site enhances 
PTEN catalytic function (Campbell et al. 2003). The tail domain is an 
important region for negative regulation of PTEN. Deletion of the tail 
activates PTEN’s ability to inhibit AKT while reducing its half-life 
(Vazquez et al. 2000). Several groups have reported that the tail 
region is a site of constitutive serine and threonine phosphorylation on 
multiple sites (Vazquez et al. 2000). Casein kinase II appears to be 
responsible for PTEN phosphorylation. It should be noted that the 
stoichiometry and sites of phosphorylation varied from group to 
group. Alanine mutations that block phosphorylation at three or more 
sites behave like tail deletions in that they have increased potency and 
reduced stability.  The mechanism through which the tail inhibits 
PTEN function appears to be through the regulation of access to the 
plasma membrane. In fact mutants that remove the tail or its 
phosphorylation sites (serine 380, threonine 383) are found on the 
plasma membrane. Interestingly, stable expression of these mutants 
requires that the catalytic site be inactivated (C124A). Therefore, it 
appears that increasing phosphorylation of the PTEN tail is likely to 
have oncogenic consequences by sequestering PTEN away from the 
plasma membrane.  
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MOLECULAR TARGETS OF PTEN 
As stated above, PTEN phosphatase activity has been observed 
against both lipid and protein substrates. Overall, the primary 
physiological substrate of PTEN appears to be the signaling lipid 
Phosphatidylinositol, (3, 4, 5) P3 (since now PIP3) (see figure 3A) 
(Maehama and Dixon, 1998; Myers et al., 1998). PIP3 is a major 
product of PI 3-kinase, which is activated by cell receptors including 
various tyrosine kinase growth factor receptors and integrins (Rameh 
and Cantley, 1999; Leevers et al., 1999). PTEN cleaves the 
3’phosphate from PIP3 to generate PIP2 (Maehama and Dixon, 1998), 
which lacks the activities of PIP3 but has its own actions on 
cytoskeleta lfunction. By antagonizing the action of PI 3-kinase (see 
figure 3B), PTEN affects a number of cell biological processes (see 
below). In addition, it can dephosphorylate the signaling molecule 
inositol (1,3,4,5)-tetrakisphosphate (Maehama and Dixon, 1998), 
although the biological importance of this activity is not yet clear.  
In vitro, PTEN can also remove phosphate residues from 
phosphotyrosine-containing peptides and proteins (Li and Sun, 1997; 
Myers et al., 1997; Tamura et al., 1998; Gu et al., 1998; Gu et al., 
1999), although the relative importance of this enzymatic function in 
vivo compared with its lipid phosphatase activity has been 
controversial.  
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 Figure 3. A.PtdIns contains a myo-inositol headgroup connected to 
diacylglycerol by a phosphodiester linkage. The numbering system of 
the inositol ring is indicated. B.The class I PI3K enzymes can 
phosphorylate the 3 position of PtdIns, PtdIns-4-P, or PtdIns-4,5-P2 to 
produce PtdIns-3-P, PtdIns-3,4-P2, or PtdIns-3,4,5-P3, respectively. 
PtdIns-3,4-P2 can also be produced by dephosphorylating the 5 
position of PtdIns-3,4,5-P3, and one enzyme that does this is an SH2-
containing 5-phosphatase called SHIP. In addition, PtdIns-3,4-P2 can 
be produced by phosphorylating the 4 position of PtdIns-3-P 
[reviewed by Fruman et al. (76)]. PTEN has been shown to 
dephosphorylate the 3 position of both PtdIns-3,4,5-P3 (26, 43) and 
PtdIns-3,4-P2 (44) to reverse the reactions catalyzed by PI3K. C. 
Major enzymatic function of PTEN. The tumor suppressor PTEN 
opposes the action of phosphoinositide 3-kinase (PI 3-kinase) by 
dephosphorylating the signaling lipid phosphatidylinositol (3,4,5)-
trisphosphate. 
.
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Two cytoplasmic phosphoprotein substrates of PTEN are focal 
adhesion kinase (FAK) and the adapter protein Shc (see figure 4), 
whereas a number of other cellular tyrosine-phosphorylated proteins 
appear unaffected by PTEN (Tamura et al., 1998; Gu et al., 1999). 
FAK and Shc are central components of distinct signaling pathways . 
The FAK signaling pathway is activated by integrins and other 
receptors and is linked to cell migration and other cellular activities. 
The Shc pathway is activated by receptors that include various 
tyrosine kinase receptors and integrins, and is part of a pathway that 
leads to activation of ERK MAP kinases. Although these in vitro 
effects have proven valuable for dissecting pathways that regulate cell 
migration (see below), analyses of cells from PTEN-knockout 
embryos fail to show changes in basal FAK phosphorylation or ERK 
activity (Stambolic et al., 1998; Liliental et al., 2000). These findings 
indicate that the major target of PTEN under steady-state conditions is 
PIP3 and not FAK, although transient changes in PTEN levels might 
nevertheless still have physiological effects on FAK/Shc activity. 
Furthermore, the G129E PTEN mutation abrogates most PTEN 
activity against PIP3, but it retains activity against peptide and protein 
substrates (Myers et al., 1998); this mutation is found in some cancers.  
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Figure 4. Reported sites of action of PTEN. Extracellular interactions 
trigger signaling from integrins and growth factor receptors. The 
majorfunction of PTEN appears to be downregulationof the PI 3-
kinase product PtdIns(3,4,5)P3, which regulates Akt and complex 
downstream pathways affecting cell growth, survival and migration. 
In addition, PTEN has weak proteintyrosine phosphatase activity, 
which may target focal adhesion kinase (FAK) and Shc, and thereby 
modulate other complex pathways. The phosphatase domain of PTEN 
(red) dephosphorylates and downregulates (red lines) substrate 
molecules. 
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MECHANISM OF PTEN TUMOR SUPPRESSION 
PTEN regulates the PI-3 kinase pathway by removing the third 
phosphate from the inositol ring of the PIP3 second messenger (Sulis 
et al. 2003; Vivanco and Sawyers , 2002). Interestingly PTEN has 
conserved this function in many animal species including mammals, 
Drosophila, and C. elegans. (see figure 1 B). Although PIP3 is able to 
bind to over one hundred cellular proteins, genetic studies have 
demonstrated that a major output of PIP3 is AKT/protein kinase B. 
Lack of PTEN in a cell leads to increased PIP3 levels and AKT kinase 
activity.  Mammalian cells lacking PTEN have increased proliferation, 
reduced apoptosis, altered migration, and increased size—all 
phenotypes that favor tumorigenesis. Downstream substrates of AKT 
that are altered genetically in malignancy include TSC2, a tumor 
suppressor mutated in the hamartoma syndrome tuberous sclerosis that 
regulates mTOR, and MDM2, an oncogene amplified in sarcomas that 
suppresses p53 function. Other AKT substrates include the FOXO 
transcription factors, p27, p21, GSK3, and BAD, which have 
important roles in the regulation of the cell cycle and apoptosis (see 
figure 5).  Re-expression of PTEN in tumor cell lines lacking the gene 
led to inhibition of AKT and a variety of outputs that included 
inhibition of the cell cycle, activation of apoptosis, rearrangement of 
the cytoskeleton, altered cellular migration, and suppression of 
angiogenesis—phenotypes that varied depending upon the cell line 
and dose of PTEN. While most PTEN phenotypes require that PTEN 
be in a catalytically active state, observations on the control of  
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Figure 5. Akt, principal effector of PTEN , interacts with several 
substrates that control various phenomena of  cell life, such as for 
example progression of cell cycle, (i.e. p27kip1 and p21cip1) and 
apoptosis (i.e.Bad and Caspase 9). 
p27 
GSK-3β 
AFX, FKHRL 
p21 
Bad 
Caspasi 9 
Glut-1, 4 
IKK 
TSC 
mTOR 
AKT 
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migration, the cytoskeleton, and the p53 pathway suggest that PTEN 
exerts PIP3-independent phenotypes (Tamura et al. 1998, Freeman et 
al. 2003). 
 
PTEN IS DEVELOPMENTALLY REGULATED AND 
NECESSARY FOR EMBRYONIC DEVELOPMENT        
Although substantial progress has been made in understanding the role 
of PTEN in tumor suppression, much less is known about its role in 
normal embryonic development (except that PTEN-knockout mice die 
early in development) or about its regulation during normal tissue 
function. 
Expression levels of PTEN protein are low in development until 
approximately day 11, when levels rise substantially in multiple 
tissues (Podsypanina et al., 1999), and the protein becomes widely 
distributed (Gimm et al., 2000). Soon after its discovery, several 
laboratories generated null mutations of the PTEN gene in mice to 
assess its function in vivo. The phenotypes differed considerably, 
presumably because of genetic differences between the mice used by 
each group.  Nevertheless, all PTEN-knockout mice die before birth, 
demonstrating a requirement for PTEN in embryogenesis (Di 
Cristofano et al., 1998; Suzuki et al., 1998; Podsypanina et al., 1999). 
The phenotypes differed substantially: one study identified major 
defects in proper differentiation and organization of the ectoderm, 
mesoderm and endoderm (Di Cristofano et al., 1998) and observed 
death by embryonic day  (E) 7.5; another found severe malformations 
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of cephalic and caudal regions, which suggested an imbalance of 
growth and patterning, and observed death by E9.5 (Suzuki et al., 
1998); a third study found severe defects by approximately E6.5, 
indicating that even the low level of PTEN protein present in early 
embryos is needed for successful embryonic development  
(Podsypanina et al., 1999). These differing results suggest a major role 
for context in PTEN functions. For example, PTEN may play 
important roles in germ layer organization or differentiation in one 
genetic background, but not in another; it may instead play crucial 
roles in regulating local apoptosis or proliferation in another setting.  
 
PTEN IN GROWTH, APOPTOSIS AND ANOIKIS 
Because a tumor suppressor might be expected to suppress cell 
proliferation, several research groups have tested whether restoration 
of PTEN expression to cells that have mutated PTEN alleles 
suppresses growth. Transient expression using plasmid or adenoviral 
PTEN vectors suppresses proliferation.  However, results are not 
always consistent, even in the same cell line. Most studies have shown 
suppression of proliferation due to arrest in G1 phase of the cell cycle 
and corresponding increases in the levels of cell cycle inhibitors such 
as p27KIP1 and decreased levels of retinoblastoma (Rb) protein 
phosphorylation (Furnari et al., 1998; Li and Sun, 1998;  reviewed by 
Tamura et al., 1999c and Simpson and Parsons,  2001). The G1 phase 
cell cycle arrest is due to the lipid phosphatase activity of PTEN 
against PIP3 (Ramaswamy et al., 1999). In fact, cell cycle effects of 
PTEN can be mimicked by SHIP-2, an enzyme that hydrolyzes 
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another phosphate group on PIP3 (Taylor et al., 2000). However, 
results using the G129E mutant provide evidence for phosphatase 
activity in G1 cell cycle arrest (Hlobilkova et al., 2000).  It should be 
emphasized that in these experiments PTEN has not been shown to be 
a physiological regulator of the normal cell cycle, since the above 
studies involved sudden restoration (and possibly overexpression) of 
an enzyme in cells adapted to proliferate in its absence. Moreover, 
normal cells expressing PTEN can undergo rapid proliferation. In fact, 
one group found that rates of cell proliferation and levels of p27KIP1 
were normal in PTEN-null fibroblasts, despite being abnormal in 
PTEN-null embryonic stem cells (Liliental et al., 2000; Sun et al., 
1999). Thus, even though sudden reconstitution of PTEN can suppress 
proliferation, the long-term role of this activity in cancer progression 
remains unclear.   
The role of PTEN in apoptosis is clearer. Re-expression of PTEN in 
several carcinoma cell lines can induce apoptosis directly (Li et al., 
1998), even though an apoptotic stimulus is often needed (Stambolic 
et al., 1998; reviewed by Tamura et al., 1999c; Simpson and Parsons, 
2001). A particularly important role of PTEN is in the anoikis, a form 
of apoptosis characterized by loss of contact with the extracellular 
matrix (Frisch and Ruoslahti, 1997). This property may be a central 
feature of normal epithelial cell function (and perhaps certain other 
cell types) that prevents growth at abnormal sites, especially in 
suspension. This anchorage dependence of survival is defective in 
many transformed and malignant cells. Reconstitution of PTEN in 
cells that have PTEN mutations restores anoikis  (Davies et al., 1998; 
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Tamura et al., 1999a; Davies et al., 1999; Lu et al., 1999).  Anoikis 
has been linked to the signaling and scaffold protein FAK (Frisch et 
al., 1996). PTEN modulates apoptosis by reducing levels of PIP3. This 
signaling lipid regulates activation of Akt Newton, 2000; Persad et al., 
2000), a well known regulator of apoptosis. Re-expression of PTEN in 
various tumor cell lines decreases PIP3 levels and reduces Akt 
activation (Stambolic et al., 1998; Haas-Kogan et al., 1998; Myers et 
al., 1998; Davies et al., 1998). The role of FAK in anoikis may 
involve at least in part its ability to increase levels of PIP3 by 
enhancing PI 3-kinase activity (Tamura et al., 1999a).  
Dephosphorylation of FAK by PTEN would enhance the effects of 
PTEN on PIP3, since FAK phosphorylation enhances PI3-kinase 
activity (Reiske et al., 1999); the combined effects of reduced PI 3-
kinase activity and direct reductions in PIP3 levels by PTEN would 
block Akt activation and enhance apoptosis.  
 
PTEN IN CELL ADHESION, MIGRATION AND INVASION 
PTEN reconstitution or overexpression inhibits cell migration 
(Tamura et al., 1998; Liliental et al., 2000). This inhibition can be 
accompanied by transient effects on cell adhesion and spreading: the 
number of focal contacts specialized contacts mediating cell-substrate 
adhesion - is reduced, and the actin cytoskeleton is altered (Tamura et 
al., 1998), although the remaining focal contacts often appear to be 
larger. The mechanisms by which focal contacts can be modulated by 
PTEN include effects on the FAK-p130-signaling pathway  (Gu et al., 
1999) and selective effects on focal contact constituents caused by 
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changes in PIP3 levels, as suggested by unrelated studies showing that 
PDGF can modulate focal contacts through PIP3 (Greenwood et al., 
2000).  PTEN suppresses migration of a variety of cell types, 
including primary human fibroblasts, non-transformed mouse 
fibroblasts, and tumor cells (Tamura et al., 1998; Tamura et al., 
1999b). PTEN-null mouse fibroblasts also show enhanced rates of 
migration, which are reduced by reintroduction of PTEN (Liliental et 
al., 2000). PTEN also suppresses tumor cell invasion, as measured by 
in vitro assays of invasion across barriers of basement membrane 
extract (Tamura et al., 1999b). It reduces rates of migration through 
several mechanisms.  
 
THE ROLE OF PTEN IN SPORADIC TUMOUR  
Several studies confirmed that PTEN was mutated in a wide variety of 
human cancer. Mutation of PTEN could occur early in tumor 
development as seen in Cowden disease and endometrial tumors (see 
figure 6) (Levine et al. 1998).  
In most cases, however, mutation of PTEN occurrs in advanced 
cancers. Such is the case for tumors of the brain, prostate, colon, and 
cervix (Rasheed et al. 1997). Early studies indicated that 10q, where 
PTEN maps (see figure 7), abnormalities are more common in 
advanced tumors  (hence the appellation MMAC). In fact the initial 
cloning studies reported PTEN/MMAC/TEP-1 (hereafter, PTEN) 
mutations in a large fraction of glioblastoma multiforme cell lines, 
xenografts, and primary tumors, as well as in smaller samples of  
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Figure 6. PTEN mutations found in human tumours and Cowden 
disease. The mutations in breast cancer (black), glioma/glioblastoma 
(blue), other tumours (green) and Cowden disease (red) are 
represented by vertical lines. Vertical lines above (or below) represent 
the frequency at which missense mutations (or nonsense and 
frameshift mutations) are found at each particular residue. The grey 
and black boxes represent the phosphatase domain and the catalytic 
core motif, respectively. 
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Figure 7. Localization of PTEN on the longe arm of chromosome 10.
Chr 10 
PTEN 
10q233 
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breast and prostate cancers (Liu et al 1997, Steck et al. 1997)), and 
subsequent analyses confirmed that homozygotic inactivation of 
PTEN occurs in a large fraction of glioblastomas (at least 30% of 
primary tumors and 50–60% of cell lines) but not in lower-grade (i.e., 
less advanced) glial tumors (Liu et al. 1997). PTEN mutations also are 
extremely common in melanoma cell lines (50%) (9), advanced 
prostate cancers (Risinger et al. 1997)), and endometrial carcinomas 
(30–50%) (Tashiro et al.1997). Although PTEN mutations are found 
predominantly in advanced glial and prostate tumors, mutations occur 
with equal frequency at all stages of endometrial cancer (Tashiro et al. 
1997), suggesting that PTEN activation is an early event in 
endometrial carcinogenesis. Whereas germ-line PTEN mutations lead 
to increased breast cancer incidence, PTEN mutations are not a 
frequent cause of familial breast cancer (Chen et al. 1998). Occasional 
PTEN mutations are reported in head and neck  (Okami et al. 1998) 
and thyroid (Dahia et al. 1998) cancers, but not in other tumors 
associated with 10q abnormalities, including meningioma (8) and lung 
cancer (Okami et al. 1998). Regarding hematological tumors, 
mutation of PTEN occurs but is uncommon in multiple myeloma and 
non-Hodgkin’s lymphoma. Moreover, PTEN protein expression is 
reduced in many types of cancer. To highlight the common cancers, 
reduced PTEN expression has been documented in 66% of 
glioblastoma, 61% of endometrial cancer, 24% of non-small cell lung 
cancer, 38% of breast cancer, 27% of ovarian cancer, 20% of prostate 
cancer, 41% of colorectal cancer with microsatellite instability, and  
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Table I. Percenteage of reduced expression of PTEN in various type 
of tumors. 
 
 
 
 
 
 
 
TUMORS 
Reduced 
expression 
of PTEN (%) 
GLIOBLASTOMA 
ENDOMETRIAL CANCER 
 
 
 
COLORECTAL CANCER 
66% 
61% 
38% BREAST CANCER 
 
 
NON-SMALL CELL LUNG CANCER 
PROSTATE CANCER 
OVARIAN CANCER 27% 
24% 
20% 
41% with microsatellite 
Instability and 17% without 
Microsatellite instability 
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 17% of colorectal cancer without microsatellite instability (see table 
I). As has been seen for mutations, reduced expression was associated 
with advanced disease. Studies of PTEN expression in breast, brain, 
tongue, gastric, esophageal, and endometrial cancer also indicated that 
reduced PTEN protein was associated with a poor prognosis for 
patients (Depowoski et al. 2001). Examination of leukemia and 
lymphoma has demonstrated that half of B cell chronic lymphocytic 
leukemias have reduced PTEN protein and that most acute myeloid 
leukemias have activated AKT associated with inactivated, 
hyperphosphorylated PTEN (Leupin et al. 2003) The weight of the 
evidence indicates that PTEN is a powerful tumor suppressor that is 
inactivated late in the course of development for most kinds of human 
cancer. 
Many reductions of PTEN protein are not due to genomic mutation 
and are of undetermined origin. In addition, reduced PTEN protein 
expression comes in many flavors. PTEN may be absent or merely 
reduced relative to normal cells; loss of expression can be seen in the 
cytoplasm, the nucleus or both.  
 
THE ROLE OF PTEN IN FAMILIAL TUMOURS 
Germ-line mutations in PTEN cause three rare autosomal dominant 
inherited cancer syndromes with overlapping clinical features: 
Cowden disease (Liaw et al. 1997;Nelen et al. 1997), Lhermitte–
Duclos disease  (Liaw et al. 1997), and Bannayan–Zonana syndrome 
(Nelen et al. 1997). These syndromes are notable for hamartomas, 
benign tumors in which differentiation is normal, but cells are highly 
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disorganized.  
Cowden disease is characterized by hamartomas in multiple sites, 
including the skin, thyroid, breast, oral mucosa, and intestine. In 
addition, about a third of patients will have macrocephaly. Affected 
females have a 30–50% incidence of breast cancer, and Cowden 
disease patients have increased risk of thyroid carcinoma ('10% 
incidence) and meningiomas (Liaw et al. 1997). Lhermitte–Duclos 
patients have multiple hamartomas, together with macrocephaly, 
ataxia, and seizures, caused by cerebellar glial tumors. Besides their 
hamartomas, Bannayan–Zonana patients exhibit macrocephaly,  
retardation, and unusual pigmentation of the penis (Nelen et al. 1997). 
Hamartomas from Cowden disease patients exhibit loss of 
heterozygosity around the PTEN locus, indicating that homozygotic 
loss of PTEN function probably is required for hamartoma formation. 
Whether the type of mutation in PTEN contributes to the distinct 
features of these three hamartomatous syndromes remains unclear, but 
other (i.e., modifying) loci probably play the primary role in 
determining the spectrum of abnormalities evoked by a given 
mutation. Indeed, recent analyses of mutant mice   suggest that genetic 
background can significantly affect the PTEN-deficient phenotype. 
However, in Cowden disease patients,  the type of PTEN mutation 
may affect the number of affected sites andyor the presence of breast 
disease (Nelen et al. 1997).  These genetic data strongly suggest that 
PTEN function is required for normal development and that loss of 
PTEN function contributes to carcinogenesis. Gene transfer and 
knockout studies have confirmed these ideas.  
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TESTICULAR TUMOURS 
Mice heterozygous for one null Pten allele (Pten+/-) are prone to 
develop different types of tumors, including teratocarcinomas (Suzuki 
et al., 1998; Di Cristofano et al., 1998; Podsypanina et al., 1999). 
Furthermore, the conditional knockout of the pten gene in primordial 
germ cells causes the development of bilateral testicular teratomas, 
which resulted from impaired mitotic arrest and outgrowth of cells 
with immature characteristics (Kimura et al., 2003). However, the 
question as to whether PTEN is involved in human germ cell tumors 
has not yet been addressed.  
Germ cell tumors of the testis (GCT) are a heterogeneous group of 
neoplasms seen mainly in young men (ages 20–40 years; Schottenfeld 
et al. 1982). Over the past several decades, the incidence of GCTs has 
been steadily increasing in the Western world (Bergstrom et al. 1996). 
Several risk factors for GCT development have been identified, which 
include cryptorchidism, spermatogenic or testicular dysgenesis, 
Klinefelter’s syndrome, prior history of a GCT, and a positive family 
history . Positive family history indicates the involvement of inherited 
predisposing factors and hence is of importance in identifying novel 
genes that may play a role in GCT development. 
GCTs are classified as seminomatous (SE-GCT) and non-
seminomatous (NSE-GCT) tumors, both of which appear to arise from 
intratubular germ cell neoplasias (ITGCN) (Ulbright, 1998; Chaganti 
& Houldsworth, 2000). SE-GCTs retain the morphology of 
spermatogonial GCs and are exquisitely sensitive to treatment by 
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radiation as well as chemotherapy (Ulbright et al. 1993). NSE-GCTs 
display embryonal and extra-embryonal differentiation patterns which 
include primitive zygotic (Embryonal Carcinoma), embryonal-like 
somatically differentiated (Teratomas), and extra-embryonally 
differentiated (Choriocarcinomas, Yolk Sac Tumours) phenotypes 
(see figure 8) Ulbright et al. 1993). They are, as a group, sensitive to 
chemotherapy, although they are less sensitive to radiation treatment 
than are SE-GCTs (Bosl et al. 1997). NSE-GCTs usually occur as 
mixed tumors, with both differentiated and undifferentiated elements 
(Ulbright et al. 1993). Among tumors with differentiated elements, 
mature teratomas exhibit the most complete differentiation, often 
presenting such cell types as cartilage, neural tissue, and mucinous 
and nonmucinous glands. These tissue elements within a teratoma, 
however, develop in an unorganized fashion. On occasion, mature cell 
types in teratoma lesions undergo malignant transformation into 
neoplastic elements that show histological features characteristic of de 
novo tumors affecting multiple cell lineages (Motzer et al. 1998). 
GCTs of all types are frequently associated with ITGCN that, often, 
progresses to invasive cancer (Vos et al., 1990; Houldsworth, 1997). 
In nearly all cases, ITGCN lesions progress to invasive lesions. Both 
SE- and NSE-GCTs are suggested to arise from cytologically identical 
ITGCN lesions, indicating a common cell of origin of all GCTs. 
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Figure 8. Different morphology of Non Seminomatous Germ Cell 
Tumors (NSGCT). embryonal and extra-embryonal differentiation 
patterns which include primitive zygotic (Embryonal Carcinoma), 
embryonal-like somatically differentiated (Teratomas), and extra-
embryonally differentiated (Choriocarcinomas, Yolk Sac Tumours) 
phenotypes 
Diff. germ cells Diff. embr/extra-embryonal 
zygote 
somatic Extra-embryonal 
ITGCN 
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MATURATION OF PRIMORDIAL GERM CELLS 
Primordial germ cells (PGCs) are first recognized in the epiblast of the 
mammalian gastrulating embryo. They migrate to the primitive streak 
mesoderm, move on to the endoderm via the allantois, and passing 
through the hindgut, reach the genital ridges. In the human, they are 
incorporated in the developing gonad by the seventh or eighth week of 
fetal life, when they are sometimes termed the gonocytes, which 
differentiate into spermatogonia during the second and third trimesters 
of pregnancy (Figure 9). In the postnatal testis, the spermatogonial 
cells in the seminiferous tubules undergo a series of mitotic divisions 
leading to the development, successively of type A, intermediate, and 
type B spermatogonia. The type B spermatogonium undergoes 
premeiotic replication and enters meiosis as the primary spermatocyte. 
A protracted prophase comprising the leptotene, zygotene, pachytene, 
diplotene, and diakinesis stages is followed by mitoses I and II, 
culminating in four haploid cells that develop into spermatids and 
spermatozoa. Extensive cell death is a striking feature of 
spermatogenesis (Matsui et al. 1998). Apoptotic cell death plays an 
important role during development by regulating the size of a lineage 
in relation to it’s local environment, survival itself being dependent 
upon availability of growth factors and their regulatory stimuli 
(Conlon et al. 1999). In the postnatal murine testis, apoptosis is 
detected in type A spermatogonia through to meiotic spermatocytes  
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Figure 9. Pathway of development of a normal spermatozoo, from the 
stage of Primordial Germ Cell (PGC) in the gastrula to mature sperm 
in adult male. Here is underlined the changing of ploidy following 
mitosis and meiosis that led from PGC, to mature sperm and finally to 
the generation of a new embryo.
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The spermatogenous cells in the adult human testis similarly undergo 
apoptosis. 
For a GCT to develop, transformation has to occur in a PGC at some 
point during these highly complex proliferation and differentiation 
programs regulated by apoptosis. The fact that adult male GCTs 
display pluripotentiality for embryonal and somatic differentiation 
suggest that, to initiate a pluripotential tumor, a PGC committed to a 
differentiation path that leads to gametogenesis must overcome a 
restriction on proliferation and initiate differentiation cascades 
normally associated with embryogenesis. The transformed PGC must 
accomplish this differentiation program without the benefit of 
reciprocal parental (genetic) contributions from fertilization, which is 
an obligate prerequisite for normal embryonal differentiation of the 
totipotential zygote. Therefore, an understanding of the mechanisms 
of human male GCT development has considerable relevance for the 
understanding of normal GC development, mechanisms of GC 
transformation, as well as the regulation of embryonal differentiation 
pathways in mammals. 
 
MOLECULAR GENETICS OF GCTS 
The molecular basis of germ cell malignant transformation is poorly 
understood. The most common genetic alterations detected in GCT 
and ITGCN are a triploid/tetraploid chromosomal complement and an 
increased copy number of 12p, which results in the hyper-expression 
of the product of the CCND2 gene, i.e.G1 cyclin D2 (Houldsworth et 
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al., 1997). On the other hand, GCTs are often accompanied by hyper-
expression of autocrine and/or paracrine growth and angiogenic 
factors (Viglietto et al., 1996; Baldassarre et al, 1997).  
Although the ITGCN cell is generally regarded as the precursor of all 
adult male GCTs, the target stage of GC development at which 
transformation occurs is not known. Two models of origin of ITGCN 
cells have been put forward. One was proposed by Skakkebaek et al. 
(see figure 10) (Skakkebaek et al. 1997; Skakkebaek et al. 1998). This 
model suggested that fetal gonocytes, which have escaped normal 
development into spermatogonia, may undergo abnormal cell division 
mediated by a kit receptor/SCF paracrine loop, leading to the origin of 
ITGCN cells. The kit receptor is normally expressed by GCs during 
the first trimester and postnatally during meiosis, whereas SCF is 
expressed by the Sertoli cells (Loveland et al. 1997) . Gonocytes 
derailed in their normal development have been postulated to be 
susceptible to subsequent invasive growth through the mediation of 
postnatal and pubertal gonadotrophin stimulation.. A second model 
proposed by Ulbright and Chaganti (Figure 11) took into account four 
established genetic properties of GCTs, i.e., increased 12p copy 
number, expression of cyclin D2 in CIS, consistent near triploid-
tetraploid chromosome numbers, and abundant expression of wild-type 
p53 (Chaganti et al. 1997) . They have postulated that the most likely 
target cell for transformation during GC development may be one with 
replicated chromosomes that expresses wild-type p53, harbors DNA 
breaks, and may be prone to apoptosis. Such a stage is represented by 
the zygotene-pachytene spermatocyte, at which a "recombination  
 34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Model of genesis of ITGCN by Skakkebaek. A normal 
PCG escaped normal development and undergoes abnormal cell 
division mediated by a kit receptor/SCF paracrine loop, leading to the 
origin of ITGCN cells . Then, loss of PTEN contributes to enforce 
neoplastic-phenotype.
PTEN loss 
Kit 
PDGFR 
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Figure 11. A diagrammatic representation of male GC development 
during a normal life span and the proposed model of GC 
transformation. The key genetic events that underlie normal male GC 
fate and embryonal development are shown with respect to their spatial 
and temporal relationships. GCT development is depicted in the 
context of normal GC biology as discussed in the text. 
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checkpoint" appears to operate (Schwartz et al. 1999) , which can 
provide an apoptotic trigger in the presence of unresolved DNA 
double-strand breaks. This stage is temporally the longest phase 
during spermatogenesis with the cell cycle machinery halted to permit 
recombinational events to complete. It also contains replicated DNA, 
and based on murine data, wild-type p53 protein is temporally 
expressed at this stage (Schwartz et al. 1999) . According to this 
model, aberrant chromatid exchange events associated with crossing-
over during zygotene-pachytene may lead to increased 12p copy 
number and overexpression of cyclin D2. Such a cell may escape 
recombination checkpoint-associated apoptotic response through the 
oncogenic effect of cyclin D2, leading to aberrant reinitiation of cell 
cycle and genomic instability (Chaganti et al. 1997). 
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AIM OF THE WORK 
 
During my work of thesis, we sought to determine whether the tumor 
suppressor lipid and protein phosphatase PTEN plays a role in the 
pathogenesis of germ cell tumors. We investigated: (1) PTEN 
expression in 60 male germ cell tumors (32 seminomas and 22 
embryonal carcinomas and 6 teratomas); (2) PTEN expression in 
intratubular germ cell neoplasia; and (3) the effects of PTEN re-
expression in an embryonal carcinoma cell line.  
We have investigated PTEN expression in 60 bioptic specimens of 
germ cell tumors (32 seminomas, 22 embryonal carcinomas and 6 
teratomas) and 22 intratubular germ cell neoplasias adjacent to the 
tumors for PTEN protein and mRNA expression. Ten testicular 
biopsies were used as controls. In the testis, PTEN was abundantly 
expressed in germ cells whereas it was virtually absent from 56% of 
seminomas as well as from 86% of embryonal carcinomas and 
virtually all teratomas. On the contrary, intratubular germ cell 
neoplasias (ITGCN) intensely expressed PTEN, indicating that loss of 
PTEN expression is not an early event in testicular tumor 
development. The loss of PTEN expression occurs mainly at the RNA 
level as determined by in situ hybridization of cellular mRNA (17/22) 
but also it may involve some kind of post-transcriptional mechanisms 
in the remaining 25% of cases. Analysis of microsatellites D10S551, 
D10S541 and D10S1765 in GCTs (n=22) showed LOH at the PTEN 
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locus at 10q23 in at least 36% of GCTs (3 embryonal carcinoma, 3 
seminoma, 2 teratoma); two  seminomas and one embryonal (13%) 
carcinoma presented an inactivating mutation in the PTEN gene 
(3/22). Finally, we demonstrated that the phosphatidylinositol 3’-
kinase/AKT pathway, which is regulated by the PTEN phosphatase, is 
crucial in regulating the proliferation of the NT2/D1 embryonal 
carcinoma cells, and that the cyclin-dependent kinase inhibitor p27kip1 
is a key downstream target of this pathway. 
The findings reported herein indicate that loss of PTEN expression 
may play a role in the development of testicular germ cell tumors and 
that the cyclin-dependent kinase inhibitor p27kip1 is a key PTEN target 
in embryonal carcinoma cells. 
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RESULTS 
A. PTEN EXPRESSION IN NORMAL TESTIS  
Normal germ cell epithelium showed positive cytoplasmic staining for 
PTEN, as observed in prostatic and endometrial epithelium (Mutter et 
al., 2000; McMenamin, et al., 1999). Intense nuclear staining also 
occurred in several cells, as reported for thyroid and endocrine 
pancreatic tumor cells (Gimm et al., 2000; Perren et al., 2000), though 
the functional meaning of nuclear PTEN staining remains unclear. See 
Figure 12 for a representative experiment. In normal testis, PTEN 
expression was heterogeneous: the outer layer of cells (spermatogonia, 
spg) stained irregularly, with several cells showing positivity for PTEN 
expression; spermatocytes (spc) and spermatids (spt) also stained 
positive for PTEN antibodies (Figure12 and 14 A). Endothelial cells 
and Sertoli cells stained positive for PTEN (Figure 12 and 14A). 
 
B. PTEN EXPRESSION IN MOUSE TESTICULAR CELLS.  
To better define the cells in which PTEN is expressed in normal testis, 
immunohistochemical analysis was performed on serial sections of 
mouse testis using antibody against PTEN protein. PTEN protein was 
widely expressed in the germinal epithelium (spermatogonia, 
spermatocytes, spermatids) and Sertoli cells, while it was not detectable 
in spermatozoa (Fig 13A). The antiserum used in this study fulfils the 
criteria of specificity. In particular, immunoadsorption tests revealed 
that the labeling was totally blocked by preincubation of the antibody 
with 10-6 M of the cognate peptide (data not shown). 
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Figure 12. Here is re-proposed the pathway of differentiation that lead 
from PGC to mature sperm (also seen in figure 9). Added with  
immunoistochemical staining to underline PTEN expression in 
spermatogonium (SPG) and spermatocyte (SPC) stage (panel on the 
right). As red line and blue arrows stress, the expression of PTEN 
drives apoptotis necessary for correct development and maturation of 
spermatozoa. 
 
spg 
spc 
PTEN 
apoptosi
s 
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It has been confirmed the differential expression of PTEN in the 
different cell types in the mouse testis, by Western blot analysis of cell 
extracts from adult mouse testis fractionated in interstitial, Sertoli, 
spermatogonia, spermatocytes, spermatids, and spermatozoa. 
Immunoblot analysis performed on cell types enriched in the different 
types of germ cells, showed a single product migrating as a 55 kDa 
protein (Fig. 13B). Among germ cells, PTEN was abundant in 
spermatogonia, present in spermatocytes and spermatids, absent in 
spermatozoa in agreement with immunohistochemical results. PTEN 
protein was also present in the interstitial and Sertoli extract cells. 
 
C. PTEN EXPRESSION IN GERM CELL TUMORS   
Subsequently we have analysed the expression of PTEN in GCTs. 
ITGCN was present in 22 tumor samples. In all cases, the neoplastic 
cells present in ITGCN showed strong PTEN staining. As with normal 
germ cells, PTEN occurred both in the nuclear and in the cytoplasmic 
compartment of precancerous cells (Figure 14B). Interestingly, in cases 
in which tubules with ITGCN were entrapped inside a fully malignant 
tumor, strong PTEN expression was observed in the cells from ITGCN 
but not in the adjacent area (Figure 14B): in fact, PTEN staining was 
weak in the nuclei and cytoplasms of cancer cells. Conversely, 
endothelial cells showed moderate to strong PTEN expression, and thus 
served as internal positive controls. 
 
 42 
 
 
 
 
 
 
 
 
        
 
 
                                                                                                      
 
 
 
 
 
 
 
Figure 13.  PTEN expression in the mouse testicular cells.  
A. Localization of the PTEN protein in sections of adult mouse testis 
by immunocytochemistry. A representative seminiferous tubule 
showing staining in spermatogonia (spg), spermatocytes (spc), 
spermatids (spt), and Sertoli cells (ser) Magnification 400X. B. 
Western blot analysis of PTEN protein in mouse adult testis (lane 1), 
interstitium (lane 2), Sertoli cells (lane 3), and in normal mouse testis 
germ cells (lane 4-7) (50g/lane). Whole lysates were detected by anti-
PTEN monoclonal serum or with anti-ERK antibodies used as internal 
standard. ERK antibodies recognize both ERK1 and ERK2, which are 
expressed at similar levels in all cell types with the exception of 
spermatozoa (Sette et al., 1999). 
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PTEN protein expression was reduced in tumors as witnessed by the 
low signal obtained per single cell and by the decreased number of 
cells/field stained with the anti-PTEN antibody (Table II). In particular, 
most embryonal carcinomas (19/22), approximately 60% of seminomas 
(18/32) and virtually all teratomas (6/6) showed no staining with anti-
PTEN antibody. Moreover, the remaining tumors showed weak and 
focal PTEN staining. A representative immunodetection experiment of 
PTEN expression is reported in Figure 14, where PTEN-negative 
seminoma, embryonal carcinoma and teratoma are shown (Figure 14C, 
D, and E, respectively).  
To verify that the monoclonal anti-PTEN antibody (clone A2B1) was 
suitable for immunostaining experiments (Figure 14 F), serial 5- the 
signal induced by the anti-PTEN antibody, demonstrating the 
specificity of the reaction. Similar results were obtained with another 
monoclonal anti-PTEN antibody (#26H9) from Cell Signaling (not 
shown). Recently, a testis-specific PTEN homologue, denoted PTEN2, 
has been described (Wu et al., 2001). However, since the C-terminal 
peptides used for the generation of antibodies used in this study, are 
present in PTEN but absent in PTEN2, it is highly unlikely that the 
antibodies recognized PTEN2 in immunostaining.  
It has been next compared the immunoistochemical PTEN expression 
with immunoblot data. First the specificity of the monoclonal PTEN 
antibody to be used in immunoblot experiments was tested. As positive 
control, it has been used the breast cancer cell line MCF7, which is 
known to express PTEN, and as negative control it has been used the 
breast cancer cell line MDA-MB-468 that bears a hemizygous deletion  
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Figure 14.  Immunoistochemical analysis of PTEN expression in 
normal testis, in situ neoplasia and germ cell tumors. A. PTEN 
expression in human normal testis. Magnification 400X . spg, 
spermatogonia; spc, spermatocytes; spt, spermatids; ser, Sertoli cells. 
B. PTEN expression in intratubular neoplasia. Magnification 400X. C. 
Seminoma with rare focal and faint positivity for PTEN. Magnification 
400X D. Embryonal carcinoma negative for PTEN staining. 
Magnification 400X. E. Teratoma negative for PTEN staining. 
Magnification 400X. F. Peptide neutralization assay. Serial sections 
derived from the same biopsy were incubated with monoclonal anti-
PTEN antibody with and without (inset) a molar excess peptide 
antigen. Magnification 150X. sections of the same samples were 
incubated with anti-PTEN antibody with and without a 10-fold excess 
of a competing peptide. As shown in the inset of Figure 1F, peptide 
competition almost completely abolished  
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No. samples Diagnosis PTEN immunohistochemistry 
10 Normal testis 
 
+++ (10/10) 
22 ITGCN 
 
+++ (22/22) 
32 Seminoma +/- (14/32) 
- (18/32) 
22 Embrional carcinoma +/- (3/22) 
- (19/22) 
6 Teratoma 
 
- (6/6) 
 
 
 
 
 
 
 
 
 
Table II. PTEN expression in germ cell tumors 
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of PTEN and a truncating mutation in exon 2 of the remaining allele, 
which results in the loss of PTEN expression (Li et al., 1999). 
The anti-PTEN antibody recognized a single band of 55-60 kDa only in 
the MCF-7 cells but not in the MDA-MB-468 cells (Figure 15A).  
Then it has been determined PTEN expression in 16 primary germ cell 
tumors (8 seminomas and 8 embryonal carcinomas) using 
immunoblotting, selecting them on the basis of PTEN expression, 
among the samples undergone immunohistochemical analysis. Proteins 
from 4 non-neoplastic testes served as controls (NT, normal testis). The 
amount of PTEN protein was high in normal testis (Figure 15B, lane 1) 
and low in several tumors (6/8 seminomas and 6/8 embryonal 
carcinomas presented low PTEN expression, respectively). See for an 
example figure 15 B. A good correlation between the immunostaining 
and immunoblot data was observed. 
Because PTEN activity prevents AKT activation in a variety of human 
tumors and cell lines (Haas-Kogan et al., 1998; Bruni et al., 2000), it 
has been investigated whether the down-regulation of PTEN observed 
in testicular tumors resulted in AKT activation, measured as increased 
phosphorylation at specific serine (ser473) and threonine (thr308) 
residues. To this end, it has been determined the expression and the 
phosphorylation status of AKT in the same representative set of tumors 
(Figure 15B). As expected, AKT phosphorylation on Ser473 was 
higher in some tumors (Figure 15B, lanes 1, 3, 4, 6, 7, 8, 10, 11, 14, 15, 
and 16) than in normal testis. Ten out of eleven tumors with low PTEN 
expression had high levels of phosphorylated Akt (Figure 15B, lanes: 1,  
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 Figure 15. Western blot analysis of PTEN expression in normal 
and neoplastic testis A. The monoclonal anti-PTEN antibody 
recognized PTEN protein in MCF7 cells but not in MDA-MB-468 cells 
used as positive and negative controls, respectively. B. PTEN 
expression and AKT phosphorylation in germ cell. Forty micrograms 
of total proteins were resolved on 10% SDS-PAGE, transferred to 
nitrocellulose filters and western blotted with anti-PTEN monoclonal 
antibody, anti-phospho-Ser473 AKT and anti-total AKT. Antibodies to 
-tubulin served as loading control. Lane NT: normal testis; 
seminomas: lanes 1-4, 9-12 ; embryonal carcinomas: lanes 5-8, 13-16. 
Films were scanned and the intensity of bands was quantified by the 
NIH Image 1.57 program.  
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4, 6, 7, 8, 10, 11, 12, 14, 15 and 16). Anti-β-tubulin antibody was used 
as a loading control. In general, PTEN expression inversely correlated 
with the level of phosphorylated Akt. Exceptions were tumor SE2 in 
lane 2, which showed low Akt phosphorylation in the presence of low 
PTEN expression and tumor SE3 in lane 3, which showed high Akt 
phosphorylation in the presence of high levels of PTEN protein. While 
we do not have any reasonable explanation for tumor SE2, Akt 
hyperexpression or activating mutations in the PI3K catalytic subunit 
may account for increased Akt activity in the case of tumor SE3 as 
recently reported (Samuels et al., 2004). 
 
D. ANALYSIS OF PTEN’S mRNA LEVEL IN GERM CELL 
TUMORS 
In order to assess whether loss of PTEN protein, demonstrated by 
immunohistochemistry and confirmed by immunoblot, was a 
consequence of reduced mRNA expression, it has been performed 
mRNA In Situ Hybridization (ISH) on a subgroup of germ cell tumors 
selected for being negative for the expression of PTEN protein (12 
seminomas, 6 embryonal carcinomas, 4 teratomas). Results are 
reported in Table II. It has been observed a direct correlation between 
the amount of PTEN protein and PTEN-specific mRNA in 75% of 
cases. The majority of seminomas (9/12, 75%), embryonal carcinomas 
(5/6, 83%) and teratomas (3/4, 100%) analysed showed reduced or no 
mRNA in tumor cells (Fig. 16B and C). An example of seminoma 
positive for PTEN’s mRNA expression is shown in figure 16 D. 
Staining for PTEN mRNA was observed instead in the samples  
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Figure 16.  In situ hybridization analysis of PTEN expression in 
normal testis and germ cell tumors. A. Expression of PTEN mRNA 
in human normal testis. Magnification 400X . B. Expression of PTEN 
mRNA in a PTEN deficient seminoma. Magnification 400X C. 
Expression of PTEN mRNA in an embryonal carcinoma negative for 
PTEN staining. Magnification 400X. D. Expression of PTEN mRNA 
in seminoma positive for PTEN staining. Magnification 400X. 
        
        
A B 
C D 
 50 
 
 
 
 
positive for PTEN protein (not shown). In all cases, non-neoplastic 
atrophic tubules, adjacent to the tumor, showed nuclear and 
cytoplasmic staining of germinal cells, thus functioning as internal 
control (Fig. 16A). Conversely, 5 out of 22 cases (23%) analysed 
retained PTEN mRNA despite absence of protein expression (Table 
III).  
 
 
E. GENETIC ANALYSIS OF PTEN IN GERM CELL TUMORS   
PCR-based analysis to determine LOH of markers spanning the PTEN 
locus was performed on a series of 22 germ cell tumor samples (12 
seminomas, 6 embryonal carcinomas and 4 teratomas) and the 
corresponding adjacent normal tissues. Results are reported in Table 
III. All samples were analysed for microsatellite markers surrounding 
the PTEN locus at 10q23 (D10S551, D10S1765 and D10S541). In 
particular, these markers present a centromere-to-telomere orientation, 
covering 5 MB of chromosome 10 that includes the PTEN locus. The 
5’ end of the PTEN gene is approximately 20 Kb downstream 
D10S1765 and the 3’ end 270 Kb upstream of D10S541 (see figure 
17). Three samples were non informative (NI) for D10S551 (see Table 
III), three were non informative for D10S1765 and four for D10S541. 
Overall, the LOH frequency in germ cell tumors was 41% (9 of 22). 
Four of 19 informative samples were homozygous for D10S551, 7 
samples exhibited apparent LOH for D10S1765 and 3 for D10S541.  
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 Figure 17. Here it is shown the position of microsatellites analyzed for 
LOH of PTEN, on chromosome 10. The 5’end of PTEN is about 20kb 
downstream of DS1765 while the 3’end about 270 kb  upstream 
D10S541
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Table III. Here they are summarized results concerning the 
investigation on LOH and point mutations. It has been used the 
following formula to calculate LOH: (peak height of normal allele 2)/ 
(peak height of normal allele 1) divided by (peak height of tumor allele 
2)/ (peak height of tumor allele 1). LOH at a single locus was 
considered present when the difference between the two alleles was 
50%. NI, not informative 
  s  22 
    21 
    20 
R233H NI  NI 19 
  s  18 
 s s  17 
    16 
   NI 15 
 s s s 14 
Y138Term   s 13 
   s  12 
 NI s  11 
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Five samples showed LOH at two loci while the majority of samples  
showed LOH for just one marker. LOH was slightly more frequent in 
embryonal carcinomas and teratomas (3 of 6 and 2/4, respectively) than 
in seminomas (3/12).  
Subsequently, we analyzed the same 22 germ cell tumors for the 
presence of mutations in the coding region of the PTEN gene by PCR 
amplifying all the nine exons of the PTEN gene and subsequent direct  
automated DNA sequencing of the PCR products. Genomic DNA 
extracted from paraffin-embedded samples was amplified using intron-
specific primers that flanked exons 1-9 as previously described (Bruni 
et al., 2000). Samples from the corresponding adjacent normal tissues 
were included as controls. Results are reported in Table III. DNA 
sequencing of exons 1-9 of PTEN gene demonstrated the existence of a 
pathogenetic mutation in three samples (2 embryonal carcinomas and 1 
seminomas): a TAT->TAG transversion at the codon 138 in exon 5 that 
caused the formation of a premature termination codon (Y138->term) in 
a patient affected by a seminoma (# 13); a transversion in the codon 
119 GTT->GGT that causes V119->G mutation in a patient affected by 
embrional carcinoma (# 10) (see figure 18); a transition CGC->CAC at 
the codon 233 in exon 7 that caused a R233->H missense mutation in 
another  patient affected by an embryonal carcinoma (# 19). These 
mutations likely impair PTEN function: the missense mutation (R233-
>H) hits a residue that has been reported to be germline mutated in a 
family affected by Cowden Disease (Liaw et al. 1997). On the other  
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Figure 18. Chromatogram inherent to mutation GTT->GGT which 
determines the mutation V119G in the 5 exon. In this example of 
seminoma, PTEN expression is manteined (see panel on the right) but 
its function is lost.
GTT 
V119 
GGT 
G119 
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hand, the mutation Y138term generates a truncated protein whose 
function is impaired. Accordingly, a mutation that hits the residue 139 
has been found in a patient affected by Cowden Disease. 
Finally, the other mutation in  the 5 exon , probably impair right 
phosphatase activity of PTEN, since it is located in the catalytic 
domain. Thus, our analysis demonstrated the presence of somatic 
mutations (at a frequency of about 9%) in sporadic germ cell tumors.  
 
 
F. REGULATION OF PTEN EXPRESSION IN EMBRYONAL 
CARCINOMA CELLS  
The finding that post-transcriptional mechanisms are involved in the 
loss of PTEN expression in at least a quarter of GCTs, made us 
investigate whether protein degradation was involved in the loss of 
PTEN expression by using the embryonal carcinoma NT2/D1 cell line 
as a model system.  
To determine the molecular mechanisms whereby PTEN expression is 
lost in neoplastic germ cells, we used a well-known model of human 
embryonal carcinoma cells: the NTERA-2 cell line (NT2/D1) 
(Andrews, 1984). Though this cell line derives from a late stage lesion 
(embryonal carcinoma cell line), and does not allow to reproduce the 
transition from early-lesion (ITGCN) to late lesion (full blown cancer), 
it still represents a good model because is amenable to manipulation in 
vitro, allows to study the mechanisms whereby PTEN expression is 
regulated in EC cells and finally allows to pinpoint the relevant 
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pathways downstream PTEN.  
Treatment of NT2/D1 cells with two highly specific proteasome 
inhibitors (the peptide aldheyde N-acetyl-leucyl-leucine norleucinal or 
LLnL and the inhibitor MG132) increased the level of PTEN. 
Treatment of NT2/D1 cells for 2, 8 or 12 hours with 20 M of MG132 
(Figure 19A, lanes MG), or 50 M of LLnL (not shown) resulted in 2-
4.5 fold increase in the level of PTEN expression compared to DMSO-
treated cells (Figure 19A, lanes C), suggesting that in embryonal level 
of PTEN RNA and protein (Figure 19B), suggesting that PTEN 
promoter methylation is not implicated in the down-regulation of PTEN 
expression in NT2/D1 cells.  
 
G. ADOPTIVE EXPRESSION OF PTEN INTO EMBRYONAL 
CARCINOMA CELLS INDUCES GROWTH ARREST  
Subsequently, we used the NT2/D1 cells also as a model system to 
determine the effects exerted by PTEN in neoplastic germ cells. 
NT2/D1 cells were plated in 10-mm dishes and transfected with wild 
type or mutant (C124S, G129E) FLAG-tagged PTEN constructs 
(FLAG-PTEN, FLAG-PTEN/C124S or FLAG-PTEN/G129E) or with 
the control empty vector. Forty-eight hours after transfection, cells 
were collected and analysed by FACS. Enforced PTEN expression in 
NT2/D1 cells resulted in G1 arrest but not apoptosis at 24-48 hours 
(Figure 20A). In fact, 50.3% of NT2/D1 cells transfected with wild 
type FLAG-PTEN were in G1 phase versus 29.4% of vector-transfected 
cells. Neither C124S nor G129E PTEN mutants suppressed growth 
(30% and 30.5% of cells were in the G1 compartment, respectively).  
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A.  
Figure 19.  Regulation of PTEN expression in embryonal 
carcinoma cells  
A. Treatment of NT2/D1 cells with with 20 M DMSO (C) or MG132 
(MG) for the indicated times (2, 8, 12 hours). B. Northern blot analysis 
of PTEN expression in NT2/D1 cells treated with solvent alone or 5 
M 5-azacytidine for 2 days. 
 58 
 
 
 
 
 
Because the G129E PTEN mutant has lost the lipid phosphatase 
activity but not the protein phosphatase activity, these findings 
demonstrate that the growth suppression induced by PTEN in NT2/D1 
cells requires the ability to dephosphorylate lipid but not protein 
substrates. Statistical analysis was performed using the one-way 
ANOVA with post-hoc multiple comparisons assessed with the 2-tailed  
Dunnett’s t test, and the differences resulted significative (p<0.05). 
Treatment with pharmacological PI3K inhibitors LY294002 or 
wortmannin for 24 h decreased the proliferation of breast cancer cell 
lines (Lu et al., 1999). To determine the relevance of the 
PI3K/PTEN/AKT pathway in embryonal carcinoma cells, we 
investigated the effects exerted by PI3K inhibitors (LY294002 and 
wortmannin) on NT2/D1 cells. As with PTEN, treatment of NT2/D1 
cells with 20 M LY294002 (or 25 M wortmannin, not shown) 
greatly reduced S phase entry as determined by flow cytometry (Figure 
20B) and BrdU incorporation (Figure 12A). Therefore, inhibition of the 
PI3K pathway induces G1 arrest in NT2/D1 cells.  
 
H. PTEN-DEPENDENT GROWTH ARREST IN EMBRYONAL 
CARCINOMA CELLS REQUIRES P27KIP1  
Previously, it has been have demonstrated that p27kip1 is a key regulator 
of the growth and differentiation of NT2/D1 cells (Baldassarre et al.,  
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 Figure 20.  PTEN-induced growth suppression in NT2/D1 cells. A. 
Flow cytometry of NT2/D1 cells transfected with wild type and mutant 
PTEN constructs. Values are means ± SD, of 3 experiments. Statistical 
analysis was performed using the one-way ANOVA with  post-hoc 
multiple comparisons assessed with the 2-tailed Dunnett’s t test. * 
p<0.05 vs Control. B. Flow cytometry analysis of NT2/D1 cells treated 
with DMSO alone or with the PI3K inhibitor LY294002. Values are 
means ± SD, of 3 experiments. Data are mean value  SD. Data are 
mean value  SD. Statistical analysis was performed using the unpaired 
2-tailed Student’s t test. *p<0.05, †p<0.01, ‡p<0.005 vs Control. 
 60 
1999; Baldassarre et al., 2000). The function of p27kip1 is regulated by 
the activity of the PTEN/PI3K/Akt pathway through different 
strategies. In different cell lines the PTEN/PI3K/Akt pathway regulates 
both expression and localization of p27kip1 (Da-Ming & Hong, 1998; 
Bruni et al., 2000; Viglietto et al., 2002). Therefore, it has been 
investigated: (1) whether inhibition of PI3K signalling either by PTEN 
or by change of localization and (2) whether p27kip1 up-regulation was 
required for the growth-inhibitory effects exerted by blocking the PI3K 
pathway.  
FLAG-PTEN expression in NT2/D1 cells or treatment with the PI3K 
inhibitor LY294002 reduced AKT phosphorylation (Figure 21A, lanes 
2 and 3, and Figure 21B, lanes 2-4, respectively), and induced a two-
fold increase in the levels of p27kip1 (Figure 21A, lane 2, and Figure 
21B, lanes 2 and 3, respectively).  
Furthermore, adoptive expression of PTEN and/or treatment of 
NT2/D1 cells with LY294002 induced cytoplamic re-localization of 
p27kip1 (Figure 22A). The effects exerted by PTEN or by LY294002 on 
p27kip1 were similar, in agreement with the concept that wild type 
PTEN as well as LY294002 block PI3K-dependent activation of Akt; 
conversely, the mutant PTEN allele G129E has no effect on the 
localization and the phosphorylation of p27kip1 (see figure 22B). 
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 Figure 21. Up-regulation of p27kip1 in NT2/D1 cells by blockage of 
the PI3K pathway. A. Immunoblot analysis of PTEN, AKT and 
p27kip1 expression in NT2/D1 cells transfected with PTEN constructs. 
Lane 1, FLAG-transfected cells; lane 2, FLAG-PTEN-transfected cells; 
lane 3, FLAG-PTEN-transfected in the presence of p27kip1 antisense 
oligonucleotides. B. Immunoblot analysis of analysis of PTEN, AKT 
and p27kip1 expression in LY290042-treated NT2/D1 cells, in the 
presence or in the absence of anti-p27kip1 antisense oligonucleotides. 
Lane 1, proliferating NT2/D1 cells; lane 2, LY290042-treated NT2/D1 
cells; lane 3, LY290042-treated NT2/D1 cells in the presence of control 
oligonucleotides; lane 4, LY290042-treated NT2/D1 cells in the 
presence of p27kip1 antisense oligonucleotides. 
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 Figure 22. Nuclear accumulation of p27kip1 in NT2/D1 cells by   
blockage of the PI3K pathway.  
A.Immunoblot analysis of p27kip1 localization on cytoplasmic and 
nuclear extracts of NT2/D1 cells treated with LY294002 or transfected 
with PTEN constructs. Lane 1, untreated mock-transfected cells; lane 
2, mock-transfected cells treated with 10 M LY294002; lane 3, wild 
type FLAG-PTEN-transfected cells; lane 4, G129E FLAG-PTEN-
transfected cells. -tubulin and SP1 were used as controls of 
fractioned proteins. B. Immunoblot analysis of p27kip1phosphorylation 
on cytoplasmic and nuclear extracts of NT2/D1 cells treated with 
LY294002 or transfected with PTEN constructs. Lane 1, untreated 
mock-transfected cells; lane 2, mock-transfected cells treated with 10 
M LY294002; lane 3, wild type FLAG-PTEN-transfected cells; lane 
4, G129E FLAG-PTEN-transfected cells
 63 
 
 
 
To determine whether p27kip1 was necessary for the growth arrest 
induced by wild type PTEN and LY294002 in NT2/D1 cells, we 
suppressed p27kip1 expression by using antisense oligonucleotides, and 
measured S phase entry by determining the rate of BrdU incorporation. 
Antisense oligonucleotides (1 M) spanning the ATG initiation codon  
of p27kip1 efficiently blocked the increase in p27kip1 expression induced 
by PTEN or LY294002 in NT2/D1 cells (Figure 23A, lane 3, and 
Figure 23B, lane 4) and almost completely rescued the growth arrest 
induced by PTEN or by PI3K inhibitors (Figure 23A and B, 
respectively).  
Transfected cells were identified by cotransfection of relevant plasmids 
with pEGFP, a plasmid encoding the eukaryotic green autofluorescent 
protein (EGFP). pFLAG-transfected cells incorporated BrdU (yellow 
arrows); whereas FLAG-PTEN-transfected cells did not (white 
arrows).However, when NT2/D1 cells were transfected with FLAG-
PTEN inthe presence of 1 M of p27kip1 antisense oligonucleotides, 
PTEN-transfected cells incorporated BrdU (yellow arrow). Analogous 
results were obtained when cells were treated with LY294002. Taken 
together, these results indicate that the cyclin-dependent inhibitor 
p27kip1 is required for PTEN growth-suppressing activity in embryonal 
carcinoma cells and that this effect is mediated by AKT. 
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Figure 23.  PTEN exerts its growth suppression activity through 
p27kip1 A. BrdU incorporation assay of NT2/D1 cells transfected with 
PTEN constructs in presence or absence of p27kip1 antisense 
oligonucleotides. First column: green FLAG-transfected cells 
incorporate BrdU (yellow arrow). Second column: green FLAG-PTEN-
expressing cells do not incorporate BrdU (white arrows). Third column: 
green FLAG-PTEN-transfected NT2/D1 cells incorporate BrdU in the 
presence of p27kip1 antisense oligonucleotides (yellow arrow). A 100X 
Neo-Achromat Zeiss lens was used. Data are mean ± SD, of 3 
experiments; p<0.01. B. BrdU incorporation assay of NT2/D1 cells 
treated with DMSO alone (column 1), LY294002 (column 2) or with 
LY294002 in the presence of excess of p27kip1 antisense 
oligonucleotides (column 3). First row: transfected cells are identified 
by green fluorescence of EGFP; second row: cells that incorporate 
BrdU are stained with Texas Red –conjugated secondary antibodies 
(red); third row: cell nuclei stained with Hoechst (blue). A 100X Neo-
Achromat Zeiss lens was used. Data are mean ± SD, of 3 experiments; 
p<0.01. 
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DISCUSSION 
 
Inactivation of the tumor suppressor gene PTEN leads to the 
development of testicular germ cell cancer in heterozygous mice 
(Suzuki et al., 1998; Di Cristofano et al., 1998; Podsypanina et al., 
1999; Kimura et al., 2003). In this study we address whether PTEN is 
also implicated in the development of human GCTs (seminomas, 
embryonal carcinomas and teratomas). Our results clearly demonstrate 
that the loss of PTEN expression marks the transition from non-
invasive ITGCN to invasive cancer, being PTEN expression retained in 
ITGCN, the presumed precursor lesion of germ cell tumors, and lost in 
tumors. Since ITGCN frequently progresses to invasive cancer, the 
findings reported in this study, suggest that PTEN loss is required at 
later stages of cancer development to facilitate the emergence of a more 
aggressive phenotype.  
This conclusion is in agreement with the concept that PTEN may be 
inactivated at different stages of tumor development (initiation and/or 
progression) in different tissues, and thus serves for different purposes 
depending on cell type (Iqbal, 2000): In endometrial cancer PTEN 
expression/activity is already absent in early, precancerous lesions 
(complex atypical hyperplasia) (Mutter et al., 2000); conversely, PTEN 
loss is associated with a high Gleason score in prostate cancer 
(McMenamin et al., 1999); with advanced pathological stage in high-
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grade glioblastomas (Wang et al., 1997; Rasheed et al., 1997), and late 
stage disease (metastatic) in melanomas (Zhou et al., 1998).  
In situ hybridization analysis of GCT samples which had lost PTEN 
protein supported the hypothesis that loss of PTEN protein reflect the 
reduction of PTEN mRNA levels. Moreover, the genetic analysis of 
GCTs performed in this study with microsatellites spanning about 5 Mb 
around the PTEN locus at 10q23 (D10S551, D10S1765 and D10S541), 
clearly implicated PTEN loss in the development of a subset of GCTs 
(approximatively 35%). Consistent with the idea that PTEN is the 
major target of deletion at 10q23 in GCTs, LOH was most frequent for 
D10S1765, which is closest to PTEN (Table III). In GCTs, loss of 
genetic material associated with chromosome 10q23 is observed in 
seminomas, embryonal carcinomas and teratomas. Moreover, DNA 
sequence analysis of exons 1-9 of the PTEN gene uncovered the 
presence of mutations in the PTEN gene in three cases (13%); in all 
cases, the inactivating mutation was found in a sample that retained a 
certain degree of PTEN expression (#10, #13, #19) and was not 
accompanied by LOH. Overall, our results demonstrate that one copy 
of PTEN is lost in 50% of GCTs. These results are consistent with 
previous studies on the cytogenetic profile of human tumors, that have 
shown a range of 10-15% loss of chromosome 10q in GCTs (Mertens 
et al., 1997), and with the report of 60% LOH and 33% mutations in 
cultured testicular cancer cell lines (Teng et al., 1997). The observation 
that about 25% of GCTs retain PTEN mRNA expression despite 
decreased PTEN protein levels, along with the finding that, in NT2/D1 
cells, PTEN expression is up-regulated by pharmacological inhibition 
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of the proteasome, indicate that increased turnover pf PTEN protein 
may account for the loss of PTEN expression in an additional 25% of 
GCTs.  
These results are in agreement with the recent finding that the 
regulation of PTEN expression may occur through the control of the 
stability of the protein (Torres J, & Pulido R, 2001; Wu et al., 2003; 
Okahara et al., 2004). However, we can not rule out the existence of 
other mechanisms, such as promoter methylation, that contribute to 
inactivate PTEN gene in GCTs, especially in those cases that did not 
apparently show LOH, mutations or retainment of PTEN mRNA.  
Previous works have failed to detect the presence of PTEN protein in 
the seminiferous tubule of the 17-day embryo in the human (Gimm et 
al., 2000) and PTEN mRNA in the mouse embryo (Lukko K et al., 
1999). However, PTEN mRNA is easily detected by Northern blot in 
the whole testis (Suzuki et al., 1998) and by immunoblot and 
immunostaining in maturating germ cells in adult testis (this work). 
Furthermore, targeted inactivation of Pten in mouse predisposes for 
development of teratocarcinomas and teratomas (Suzuki et al., 1998; 
Di Cristofano et al., 1998; Podsypanina et al., 1999; Kimura et al., 
2001).    
In the testis, germ cells undergo a complex program of proliferation 
and differentiation to form mature sperms (Chaganti & Houldsworth, 
2000). Correct proliferation and apoptosis is required to regulate the 
size of cell lineages and the timing of differentiation (Matsui, 1998; 
Chaganti & Houldsworth, 2000). Therefore, the loss of PTEN 
expression observed in GCTs may serve multiple purposes in germ cell 
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transformation. The window in which PTEN is expressed in mouse and 
human testis, as observed in this work (spermatogonia -> 
spermatocytes -> spermatids), overlaps the timing of massive apoptosis 
that occurs during maturation of germ cells in the seminiferous tubule 
after birth (Chaganti & Houldsworth, 2000). By preventing apoptosis-
driven germ cell selection and maturation, PTEN loss would allow 
clones of germ cells to elude programmed cell death and undergo 
malignant transformation. In agreement with this thought, the targeted 
disruption of Akt1 in the mouse, as well as the “knockin” mice of Stem 
Cell Factor/Kit receptor mutated in the docking site for the regulatory 
subunit of the PI3K, attenuates spermatogenesis and induces testicular 
atrophy, due to increased apoptosis restricted to the germ cell 
compartment (Chen et al., 2001).  
PTEN loss may also result in unrestrained cell cycle progression and 
prevention of terminal differentiation. Accordingly, a recent paper has 
suggested that estrogen-mediated PTEN down-regulation markedly 
increases the growth of primordial germ cells in culture and that PTEN-
deficient germ cells are much more sensitive to tumorigenic 
transformation induced by proliferative stimuli (Moe-Behrens et al., 
2003). Indeed, primordial germ cells from pten-/- mice exhibit an 
increased proliferative capacity (Kimura et al., 2003). 
The serine/threonine kinase PKB/Akt is an important cellular target 
downstream PTEN that transmits proliferative and anti-apoptotic 
signals (Datta et al., 1999). Accordingly, the loss of PTEN in GCTs 
inversely correlated with Akt activation. Moreover, the adoptive 
expression of PTEN in embryonal carcinoma NT2/D1 cells and 
 69 
pharmacological inhibition of the PI3K pathway induced a reduction in 
the level of Akt activation.  
Blockage of the PI3K/PTEN/Akt pathway arrests the growth of 
embryonal carcinoma cells. PTEN-transfected or LY294002-treated 
NT2/D1 cells accumulate in G1 phase but show no sign of apoptosis, at 
least after 24-48 h. Defective regulation of cell cycle progression in 
PTEN-deficient germ cells may depend either on increased expression 
of cyclins or on decreased expression of CDK inhibitors. In fact, Akt 
increases the stability of cyclin D1 by suppressing glycogen synthase 
kinase-3 (GSK-3) activity, which targets cyclin D1 to phosphorylation-
mediated degradation (Diehl et al., 1998). As the threonine residue 
phosphorylated by GSK-3 is highly conserved in all D-type cyclins, it 
is likely that Akt regulates also the levels of cyclin D2 and D3. Thus, 
the loss of PTEN function may contribute to the overexpression of 
cyclin D2 frequently observed in germ cell tumors (Chaganti & 
Houldsworth, 2000).  
On the other hand, the cyclin-dependent kinase inhibitor p27kip1 is a key 
target downstream the PI3K/Akt signalling pathway (Bruni et al., 
2000). Also in embryonal carcinoma cells the effects exerted by 
inhibition of the PI3K/Akt pathway on cell cycle progression are 
dependent on p27kip1. In fact, our results demonstrate that the adoptive 
expression of PTEN and the pharmacological inhibition of PI3K 
activity with LY294002 moderately up-regulates p27kip1 in NT2/D1 
cells and that suppression of p27kip1 synthesis by antisense 
oligonucleotides prevents growth arrest induced either by PTEN or by 
LY294002. It is noteworthy that the PTEN mutant, which lacks lipid 
 70 
phosphatase activity but retains protein phosphatase activity (i.e. 
G129E) neither induces p27kip1 expression nor blocks S phase entry. 
The PI3K pathway also regulates sub-cellular localization of p27kip1 
through Akt-dependent phosphorylation of p27kip1 (Viglietto et al., 
2002). Accordingly, PTEN-dependent inactivation of Akt in NT2/D1 
cells results in the accumulation of p27kip1 in the nuclear compartment. 
This suggests that regulation of p27kip1 localization may contribute, 
along with regulation of p27kip1 expression, to the proliferative arrest 
induced either by PTEN or by LY294002 in NT2/D1 cells. 
In conclusion, inactivation of PTEN is a critical step in the progression 
of germ cell cancer, and the cyclin-dependent kinase inhibitor p27kip1 is 
a key target of PTEN signalling pathway. Further studies are necessary 
to identify the molecular targets that act downstream PTEN in the 
transformation of the germ cell.  
 
MATERIALS AND METHODS 
Preparation of mouse testicular cells 
Testicular cells were prepared from testes of adult CD1 mice (Charles 
River Italia). Testes were freed from the albuginea membrane, and 
digested for 15 min in 0.25% (w/v) collagenase (type IX, Sigma) at 
room temperature under constant shaking. Seminiferous tubules were 
cut into pieces, with a sterile blade and further digested in minimum 
essential medium containing 1 mg/ml trypsin for 30 min at 30°C. 
Digestion was stopped by adding 10% fetal calf serum; released germ 
cells were collected after sedimentation (10 min at room temperature) 
of tissue debris. Germ cells were centrifuged for 13 min at 1,500 rpm at 
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4°C and the pellet resuspended in 20 ml of elutriation medium (120.1 
mM NaCl, 4.8 mM KCl, 25.2 mM NaHCO3, 1.2 mM MgS4 (7H2O), 1.3 
mM CaCl2, 11 mM glucose, 1X essential amino acid (Life 
Technologies, Inc.), penicillin, streptomycin, 0.5% bovine serum 
albumin. Pachytene spermatocyte and spermatid germ cells were 
obtained by elutriation of the unfractionated single cell suspension as 
described elsewhere (Meistrich, 1977). Homogeneity of cell 
populations ranged between 80 and 85% (pachytene spermatocytes) 
and 95% (spermatids), was routinely monitored morphologically. 
Mature spermatozoa were obtained from the cauda of the epididymus 
of mature mice as described previously (Sette et al., 1997). 
Spermatogonia and Sertoli cells were obtained from prepuberal mice as 
previously described (Rossi et al., 1993; Grimaldi et al., 1993). 
 
Cell lines and Reagents 
The embryonal carcinoma NT2/D1 and the breast MCF7 and MDA-
MB-468 tumor cell lines that have been used in this study are described 
elsewhere (Lu et al., 1999; Andrews, 1984). Cells were grown in 
Dulbecco’s modified Eagle's Medium (DMEM) containing 10% foetal 
calf serum (FCS) (Invitrogen). MG132 and 5-aza-cytidine were from 
Sigma-Aldrich (St. Louis, MO, USA).  
 
Tissue samples and Immunohistochemistry  
Paraffin-embedded specimens were obtained from the di Scienze 
Biomorfologiche e Funzionali, Università Federico II (Naples, Italy). 
For PTEN detection, sections were dewaxed and incubated with 
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primary antibody for 1 h at room temperature. The conventional avidin-
biotin complex procedure was used according to manufacturer’s 
protocol (LSAB Plus DAKO, Carpinteria, CA, USA). Monoclonal anti-
PTEN antibodies were purchased from Santa Cruz Biotechnology Inc. 
(clone A2B1) and from Cell Signaling (#26H9). Positive signal was 
revealed by DAB chromogen, according to the supplier's conditions. 
Nuclei were counterstained with Mayer hematoxylin. For peptide 
neutralization control, the reaction with anti-PTEN antibody was 
preceded by overnight incubation with a ten-fold excess of the 
corresponding peptide antigen (Santa Cruz Biotechnology, Inc.). 
 
In Situ Hybridization 
In situ hybridization was performed using biotin-labelled probes at 
5’OH, which were obtained tailing reaction using biotin-dUTP as 
marker. Hybrid detection was achieved by amplification using 
biotinylated tyramide (Gen Point K620 Kit, DAKO, Carpinteria, CA, 
USA). Sections were prepared from each sample and assayed according 
to the instructions of the Dako Gen Point K620 Kit. Briefly, sections 
were deparaffinized, re-hydrated, treated with proteinase K (6g/ml) in a 
buffer of Tris-HCl 0.05M, pH7.6, and then incubated in 0.3% H2O2, at 
RT, for 20 minutes, to quench endogenous peroxidase. Optimal 
hybridization and stringent wash temperatures were determined and 
slides were rinsed in the stringent solution provided with the kit. 
Amplified detection was performed using an anti-digoxigenin antibody 
coupled to a peroxidase (HRP) which precipitated biotinylated 
tyramide. The precipitated biotin bound to streptavidin-linked HRP, 
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which in turn precipitated the dimethylaminobenzidine (DAB) 
chromogen provided with the kit. Nuclei were counterstained with 
Mayer's hematoxylin. Negative controls were obtained using an anti-
sense probe. 
 
Protein extraction and immunoblotting 
Total proteins were prepared as described (Baldassarre et al., 1999a). 
Differential extraction of nuclear or cytoplasmic proteins was obtained 
by lysing cells in ice-cold Nonidet-P40 (NP-40) lysis buffer (0.2% NP-
40, 10 mM Hepes pH 7.9, 1 mM EDTA, 60 mM KCl) supplemented 
with protease and phosphatase inhibitors (aprotinine, leupeptine, 
PMSF, and okadaic acid) and incubated on ice for 5 min. The cytosolic 
fraction was collected by centrifugation. Nuclei were separated through 
a 30% sucrose cushion and lysed by resuspension in ice-cold 
hypertonic buffer (250 mM Tris-HCl pH 7.8, 60 mM HCl 
supplemented with phosphatase and protease inhibitors) followed by 
repeated cycles of rapid freeze and thaw. Proteins were separated by 
electrophoresis in SDS-containing polyacrylamide gels, transferred to 
nitrocellulose membranes (Hybond C, Amersham Pharmacia Biotech, 
Inc.), blocked in 5% non-fat dry milk, incubated with primary and 
secondary antibodies for 2 hours and 1 hour, respectively, and revealed 
by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech, 
Inc.). Polyclonal antibodies to phospho-AKT-Ser473 and AKT were 
purchased from New England Biolabs (Lake Placid, NY); monoclonal 
anti-p27kip1 and anti-ß-Tubulin were acquired, respectively, from 
Transduction Laboratories and NeoMarkers. Two PTEN antibodies 
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were used in this study both for immunoblot and immunostaining: a 
monoclonal antibody elicited to a C-terminal peptide (clone A2B1) 
from Santa Cruz inc. and a monoclonal antibody elicited to a C-
terminal peptide (PTEN 26H9) from Cell Signaling. The anti phospho-
Akt motif antibody was from Cell Signaling (#9611).  
 
Vectors and Transfections 
The PTEN constructs are described elsewhere (Bruni et al., 2000). 
Transfection experiments were performed as described (Baldassarre et 
al., 1999). NT2/D1 cells were seeded at a density of 2x106 cells per 
100-mm dish. The next day, cells were transiently transfected by the 
lipofectamine 2000 procedure (Invitrogen). Forty-eight hours post-
transfection, cells were scraped into ice-cold PBS and lysed in NP-40 
lysis buffer. Where needed, the p27kip1 antisense oligonucleotides (5'– 
GTCTCTCGCACGTTTGACAT -3') were used at a concentration of 1 
M. 
 
DNA preparation and mutation analysis by direct DNA sequencing 
Paraffin-embedded germ cell tumors and the corresponding adjacent 
normal tissue samples were selected from the pathology files of 
Dipartimento di Anatomia Patologica, Università Federico II (Naples, 
Italy). Genomic DNA from 22 testes (normal or cancer tissues) was 
isolated with a High Pure polymerase chain reaction (PCR) Template 
Preparation Kit (Roche Molecular Biochemicals, Mannheim, Germany 
and the PTEN mutation status was determined. Briefly, DNA from 
tumor samples and from the corresponding normal tissues was 
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extracted from 3-4 8- thick serial sections and subjected to PCR 
amplification for exons 1-9 as previously described (Scala et al., 1998; 
Bruni et al., 2000). PCR amplification of each single PTEN exon was 
performed by use of intronic primers designed at the 5’ and 3’ ends of 
each exon, followed by reamplification with nested primer pairs. 
Primer sequences for PCR amplification of each PTEN exon were 
previously reported (Steck et al, 97). Amplified DNA was purified 
using Microspin S300HR Columns (Pharmacia Biotech) and sequenced 
using the Big Dye Terminator cycle sequencing kit (ABI PRISM, 
Applied Biosystems, CA) and the ABI 3100 PRISM DNA sequencer 
(Applied Biosystems). 
 
LOH analysis at the PTEN locus 
LOH on chromosome 10 was studied by PCR-based microsatellite 
analysis as previously described (Mutter et al., 2002). Three 
polymorphic markers spanning the PTEN gene (D10S551, D10S1765, 
D10S541) were selected to cover deletions at the whole PTEN locus on 
chromosome 10q23. DNA from normal testis adjacent to tumors on 
histological sections from the same patient was used as reference. LOH 
was calculated according to the following formula: (peak height of 
normal allele 2)/(peak height of normal allele 1) divided by (peak 
height of tumor allele 2)/(peak height of tumor allele 1). LOH at a 
single locus was considered present when the signal corresponding to 
one allele showed at least a 45% reduction of intensity.  
 
Immunofluorescence analysis 
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5-Bromo-2’deoxyuridine-5’-monophosphate (BrdU) incorporation 
assay was performed as described previously (Baldassarre et al., 1999). 
Briefly, 5 X 105 cells were transfected with 6 g each of control empty 
vector or of wild type or mutant PTEN constructs, respectively, 
together with 3 g of a vector encoding green fluorescent protein 
(Clontech). Labelling was carried out as recommended by the 
manufacturer (Roche). Fluorescence was visualized with Zeiss 140 
epifluorescent microscope equipped with filters that discriminated 
between Texas Red and fluorescein. All assays were performed 3 times 
in duplicate.  
 
Fluorescence-activated cell sorter (FACS) analysis 
Cells were washed into ice-cold PBS and fixed by adding drop-wise 
ice-cold 70% ethanol. Fixed cells were washed with cold PBS, labelled 
with 10 g/ml propidium iodide (Sigma) and 5 g/ml Rnase A (New 
England Biolabs) and analysed with a FACScan flow cytometer 
(Becton Dickinson, San Jose, CA) interfaced with a Hewlett Packard 
computer (Palo Alto, CA). Cell cycle analysis was performed with the 
CELL-FIT programme (Becton Dickinson). All FACS were performed 
in triplicate. 
 
Northern blot analysis  
Northern blot analysis was performed according to a standard 
procedure. In brief, equal amounts of total RNA (20 g/lane) were 
denatured and resolved electrophoretically through formaldehyde-
agarose gels. The RNA was transferred onto a nylon membrane and 
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cross-linked by UV irradiation, Human PTEN cDNA was labeled with 
32P-dCTP using a random primer labeling kit (Amersham Pharmacia 
Biotech), and hybridization was performed at 42°C in the presence of 
50% formamide. 
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